Bio-Techne (NASDAQ:TECH – Get Free Report) and Elevation Oncology (NASDAQ:ELEV – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.
Valuation & Earnings
This table compares Bio-Techne and Elevation Oncology”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bio-Techne | $1.17 billion | 10.07 | $168.10 million | $0.94 | 78.99 |
Elevation Oncology | N/A | N/A | -$45.70 million | ($0.82) | -1.02 |
Bio-Techne has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Bio-Techne | 12.86% | 12.76% | 9.59% |
Elevation Oncology | N/A | -59.73% | -40.05% |
Risk & Volatility
Bio-Techne has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Bio-Techne and Elevation Oncology, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bio-Techne | 0 | 3 | 5 | 0 | 2.63 |
Elevation Oncology | 0 | 0 | 6 | 0 | 3.00 |
Bio-Techne presently has a consensus target price of $82.00, indicating a potential upside of 10.44%. Elevation Oncology has a consensus target price of $7.20, indicating a potential upside of 757.76%. Given Elevation Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Elevation Oncology is more favorable than Bio-Techne.
Institutional and Insider Ownership
98.9% of Bio-Techne shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 3.9% of Bio-Techne shares are held by insiders. Comparatively, 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Bio-Techne beats Elevation Oncology on 8 of the 13 factors compared between the two stocks.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
About Elevation Oncology
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.